Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06538857 | CEB-01 in Locally Resectable Pancreatic Cancer | recruiting | Phase 2 | 39 | CEBIOTEXINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT06741020 |
| Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma(HAICI) |
| recruiting |
| Phase 1 / Phase 2 |
| 10 |
| Zhejiang Cancer HospitalOTHER |
| 1 |
| May 23, 2025 |
| clinicaltrials |
| NCT04611165 | Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC(Nextrah) | completed | Phase 2 | 50 | National Cancer Center, KoreaOTHER_GOV | 1 | May 22, 2025 | clinicaltrials |
| NCT06984718 | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | not yet recruiting | Phase 2 | 120 | AkesoINDUSTRY | 0 | May 22, 2025 | clinicaltrials |
| NCT06978933 | FGF19 Overexpression Combination Unified Study in HCC-19(FOCUS-19) | recruiting | Phase 2 | 42 | RenJi HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06280105 | A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib | recruiting | Phase 2 | 40 | Meng Chao Hepatobiliary Hospital of Fujian Medical UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06339424 | Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma(PhotonAB) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06911255 | Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 24 | Yoon Jun KimOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04965311 | Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy | terminated | Phase 2 | 4 | OHSU Knight Cancer InstituteOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04521153 | Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma | active not recruiting | Phase 2 / Phase 3 | 294 | Shanghai Zhongshan HospitalOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma(SIRCCA) | terminated | Phase 2 / Phase 3 | 89 | Sirtex MedicalINDUSTRY | 8 | May 9, 2025 | clinicaltrials |
| NCT06963060 | Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)(GALENT-BT) | enrolling by invitation | Phase 2 | 44 | Wei GongOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06438822 | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma | recruiting | Phase 2 | 51 | West China HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02983578 | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | active not recruiting | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT04203641 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 28 | Helix BioPharma CorporationINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT05251233 | Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy | terminated | Phase 2 | 56 | Washington University School of MedicineOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05750030 | FMT in IT-refractory HCC - FAB-HCC Pilot Study | completed | Phase 2 | 12 | Medical University of ViennaOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06958484 | Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence | not yet recruiting | Phase 2 | 60 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT01754987 | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | completed | Phase 1 / Phase 2 | 5 | Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06956716 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT05239169 | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | completed | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06420440 | Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model | recruiting | Phase 2 | 160 | Chen XiaopingOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT03374852 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT06904196 | Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC | recruiting | Phase 2 | 78 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06946849 | Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study(SED-RO-ICC) | not yet recruiting | Phase 2 | 76 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT02230176 | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II(OCCLURANDOM) | completed | Phase 2 | 84 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT05448677 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma(ABE-LIVER) | terminated | Phase 2 | 3 | University Hospital, GrenobleOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06935175 | A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 53 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT02234986 | A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | completed | Phase 2 | 35 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT03861702 | Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: | completed | Phase 2 | 28 | Nelson YeeOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT04634058 | PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment | active not recruiting | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05673811 | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer(VIRAGE) | completed | Phase 2 | 112 | Theriva Biologics SLINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT05915351 | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) | active not recruiting | Phase 2 | 28 | University of Kansas Medical CenterOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04000737 | YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 62 | Yiviva Inc.INDUSTRY | 4 | Apr 13, 2025 | clinicaltrials |
| NCT05565794 | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | terminated | Phase 2 | 2 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06355427 | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma(FAPIChol) | recruiting | Phase 2 / Phase 3 | 81 | Mara Veenstra, MDOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06860477 | Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) | recruiting | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911086 | SH-LPS System in Preoperative Planning for Liver Resection | not yet recruiting | Phase 2 / Phase 3 | 100 | Zhejiang Cancer HospitalOTHER | 0 | Apr 4, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT04316182 | Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)(ACTION) | completed | Phase 2 | 24 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06903273 | Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma(TisGCS for BTC) | not yet recruiting | Phase 2 | 35 | National Cheng-Kung University HospitalOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06900478 | Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC | not yet recruiting | Phase 2 | 25 | Hua LiOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 23, 2025source: clinicaltrials